Lite Access Technologies Inc.
LTCCF News Today: Stay Updated with the Latest Lite Access Technologies Inc. News in Real Time
Find LTCCF news now at Meyka AI. Stay informed with the latest Lite Access Technologies Inc. stocks updates, including price news, market analysis, and expert insights.
India Markets March 17: Sensex, Nifty Rebound as LPG Flow Eases
Sensex Nifty today: Indian equities rebounded over 1% as LPG flow fears eased after U.S.-led escorts and India-flagged carriers crossed Hormuz. Banks, autos, and cement led gains while high Brent, ru‑
William Blair Maintains Outperform on Bumble Inc. (BMBL) March 16, 2026
BMBL analyst rating: William Blair and Deutsche Bank maintained ratings on March 16, 2026; implications and Meyka grade B
Germany Special Fund March 17: 10% Investment Quota on Track, H2 Boost
Germany special fund set to activate as Berlin targets a 10% core-budget investment quota by 2026, with first impacts expected in H2 2026. What it means for infrastructure spending Germany, data hubs,
Hyperliquid USD Climbs 6.08% as Stablecoin Reserves Hit $880M
HYPEUSD surges 6.08% daily as Hyperliquid’s stablecoin reserves reach $879.59M, signaling strong platform liquidity and institutional confidence.
H.C. Wainwright Maintains Buy on Savara Inc. (SVRA) March 2026
H.C. Wainwright maintains Buy on Savara Inc.; SVRA analyst rating held ahead of August PDUFA
AirSculpt (AIRS) NASDAQ +51% after 12b-25 filing 16 Mar 2026: earnings Mar 20
AIRS stock jumps after AirSculpt files 12b-25; we preview Mar 20 earnings and Meyka AI outlook
Leerink Maintains Outperform on Spyre Therapeutics, Inc. (SYRE) March 16, 2026
Leerink maintains Outperform on Spyre; SYRE analyst rating stays positive on March 16, 2026
Market closed: Almonty (AII.TO TSX) ahead of 19 Mar earnings: tungsten will set tone
AII.TO stock trades C$26.34 ahead of 19 Mar 2026 earnings; we review drivers, metrics and Meyka AI forecast
William Blair, Leerink Maintain Outperform on Structure Therapeutics (GPCR) Mar 2026
Two firms maintain Outperform on Structure Therapeutics; GPCR analyst rating stays positive after March 16, 2026 updates